telmisartan has been researched along with nisoldipine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appel, D; Benndorf, RA; Böger, RH; Maas, R; Rudolph, T; Schulze, F; Schwedhelm, E; Silberhorn, E | 1 |
| Appel, D; Bajcetic, M; Benndorf, RA; Böger, RH; Maas, R; Riekhof, D; Schulze, F; Schwedhelm, E | 1 |
| Appel, D; Benndorf, RA; Böger, R; Gehling, UM; Hossfeld, DK; Maas, R; Rogiers, X; Schlagner, K; Schwedhelm, E; Silberhorn, E | 1 |
| Appel, D; Benndorf, RA; Böger, RH; Maas, R; Schwedhelm, E; Wenzel, UO | 1 |
1 review(s) available for telmisartan and nisoldipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for telmisartan and nisoldipine
| Article | Year |
|---|---|
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Body Mass Index; Calcium Channel Blockers; Cohort Studies; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Nisoldipine; PPAR gamma; Telmisartan | 2006 |
Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Benzimidazoles; Benzoates; Biological Availability; Calcium Channel Blockers; Dizziness; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Edema; Female; Half-Life; Headache; Humans; Hypertension; Male; Middle Aged; Nisoldipine; Single-Blind Method; Telmisartan; Time Factors | 2007 |
Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antigens, CD; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Colony-Forming Units Assay; Endothelial Cells; Female; Humans; Hypertension; Male; Middle Aged; Nisoldipine; Phenotype; Stem Cells; Telmisartan | 2007 |
Telmisartan improves endothelial function in patients with essential hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Nisoldipine; Prospective Studies; Single-Blind Method; Telmisartan; Treatment Outcome; Vascular Resistance; Vasodilation | 2007 |
10 other study(ies) available for telmisartan and nisoldipine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |